What is market sentiment?

Market sentiment is the overall attitude of investors toward a particular security or the financial market as a whole. It reflects whether investors are feeling bullish (optimistic) or bearish (pessimistic) based on price action, news flow, economic indicators, and collective psychology. Kinvestor tracks real-time market sentiment across major indices and individual equities.

How does financial news affect stock prices?

Financial news affects stock prices by shifting investor sentiment. Positive earnings reports, strong economic data, or favorable Fed decisions typically boost stock prices, while negative news can trigger sell-offs. The speed and magnitude of price moves depends on whether the news beats or misses market expectations.

What are stock market movers?

Stock market movers are stocks with significant price changes — either up (gainers) or down (losers) — within a trading session. Movers are typically driven by earnings reports, analyst upgrades or downgrades, macroeconomic news, or major corporate announcements. Kinvestor tracks the biggest movers in real time across the S&P 500, NASDAQ, and Dow Jones.

What is earnings season?

Earnings season is the period each quarter when publicly traded companies report their financial results. It occurs four times per year: January–February (Q4 results), April–May (Q1 results), July–August (Q2 results), and October–November (Q3 results). During earnings season, stocks often experience heightened volatility as results beat or miss analyst expectations.

What is financial intelligence?

Financial intelligence is the ability to understand and interpret financial data, market trends, news, and sentiment to make informed investment decisions. It combines real-time market data, news aggregation, sentiment analysis, and economic indicators into actionable insight. Kinvestor is a financial intelligence platform that aggregates these signals in one place.

◆ NeutralNVO

Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation

GlobeNewswire Inc.·July 31, 2026

Novo Nordisk announced that ziltivekimab failed to meet its primary endpoint in the ZEUS phase 3 trial, showing no significant reduction in major adverse cardiovascular events (MACE) despite achieving the expected biological effect of IL-6 pathway inhibition. The drug demonstrated a hazard ratio of 0.99 versus placebo in patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation. The company will take a non-cash impairment charge in Q3 2026 but maintains its 2026 profit outlook and plans to continue two additional cardiovascular trials (HERMES and ARTEMIS) expected to report in H1 2027.

Read Full Article at GlobeNewswire Inc. →

← Back to Financial Intelligence